ライフサイエンスコーパス: cell proliferative response

1 g a significant HER-2/neu protein-specific T-cell proliferative response.

2 , that generated a low-level but clear-cut T cell proliferative response.

3 s nor everolimus could inhibit the CD4CD28 T-cell proliferative response.

4 expression was associated with an impaired T cell proliferative response.

5 cells, and elicits a robust TLR9-dependent B cell proliferative response.

6 also abolishes primary mitogen-induced liver cell proliferative response.

7 amma, TNF-alpha, and IL-6 in the augmented T cell-proliferative response.

8 ergic subjects but did not change in vitro T-cell proliferative responses.

9 ory mediators, and failed to induce robust T cell proliferative responses.

10 by significant adaptive CD4(+) and CD8(+) T cell proliferative responses.

11 mia was not associated with an increase in T cell proliferative responses.

12 ted in a significant enhancement of T-helper cell proliferative responses.

13 t spleen APC in vitro leads to normal CD4+ T cell proliferative responses.

14 involved in the ability of FDC to inhibit T-cell proliferative responses.

15 e potency of APCs and boost mitogen-driven T-cell proliferative responses.

16 er, mIEC did not inhibit splenic alphabeta T cell proliferative responses.

17 nt reduction in both MBP- and PLP-specific T cell proliferative responses.

18 ly suppressed allogeneic CD4(+) and CD8(+) T cell proliferative responses.

19 ion and cell death, which are hallmarks of B cell proliferative responses.

20 ncreasing cholesterol efflux suppressed stem cell proliferative responses.

21 ccompanied by diminished antigen-specific, T-cell proliferative responses.

22 or antibody binding and induction of human T-cell proliferative responses.

23 mparable levels of IL-2 and IL-4 and similar cell proliferative responses.

24 al blood lymphocytes and better priming of T-cell proliferative responses.

25 nges paralleled reduced IL-2 secretion and T cell proliferative responses after TCR-CD28 stimulation

26 onstruct produced antibodies and exhibited T-cell proliferative responses against core or envelope.

27 The frequency of T-cell proliferative responses against VP2 was significant

28 ignificantly increased autoantigen-induced T cell proliferative responses along with greater numbers

29 on of innate immune responses and adaptive T cell proliferative responses, along with only transient

30 ides containing these sequences stimulated T cell proliferative responses, although less intensely th

31 ld increase in the median p24-induced CD4+ T-cell proliferative response and a 57% increase in the nu

32 of E4 and E1 had little impact on the CD4 T-cell proliferative response and cytolytic activity of CD

33 creased its effectiveness in costimulating T cell proliferative response and early IL-2 production in

34 The in vitro splenic T cell proliferative response and induction of IFN-gamma t

35 characterized by antigen-specific impaired T cell proliferative responses and a distinct pattern of c

36 e treated with recombinant Map had reduced T cell proliferative responses and a significantly reduced

37 mpared with Ab positivity, we assessed the T-cell proliferative responses and Ab responses (islet cel

38 raft histopathology as well as anti-HLA-A2 T-cell proliferative responses and anti-HLA-A2 antibody de

39 Primary T cell proliferative responses and cytokine production (in

40 g that anti-TNF treatment in vivo enhances T cell proliferative responses and cytokine production pro

41 B-cell proliferative responses and differentiation to immu

42 Allogeneic C3H/HeJ (C3H; H2k) T-cell proliferative responses and generation of cytotoxic

43 T-cell proliferative responses and immunoglobulin G antibo

44 ration of T-regulatory cells that suppress T-cell proliferative responses and induce tolerance.

45 insight into how TNF may inhibit endothelial cell proliferative responses and modulate angiogenesis i

46 significant levels of OVA-specific CD4(+) T cell proliferative responses and OVA-induced IFN-gamma a

47 n, significant levels of OVA-specific CD4+ T cell proliferative responses and OVA-induced IL-4 and IL

48 In the mucosa, both Peyer's patch T cell proliferative responses and OVA-specific fecal IgA

49 In contrast, Th cell proliferative responses and secretion of cytokines

50 lsed DC can induce both E7-specific CD4(+) T-cell proliferative responses and strong CD8(+) CTL respo

51 Ex vivo grass antigen-driven T-cell proliferative responses and the frequency of IL-4(+

52 Although we found both a high CD4(+) T cell-proliferative response and TH2 cytokines production

53 and/or SRL both in vitro (by inhibiting of T-cell proliferative response) and in vivo (by inhibiting

54 pecific intrahepatic and peripheral CD4(+) T cell proliferative responses, and cytokines (enzyme-link

55 globulin A (IgA)- and IgG-secreting cells, T-cell proliferative responses, and gamma interferon secre

56 n of maturation markers, IL-12 production, T cell proliferative responses, and IFN-gamma production.

57 They elicited only weak allogeneic T-cell proliferative responses, and repeated stimulation i

58 enhancement in anti-CD3-stimulated CD4(+) T-cell proliferative responses, and this proliferation was

59 The results suggest that HHV-8 T cell proliferative responses are common in HIV-negative

60 llergen-driven IL-4(+) CD4(+) T cells, and T-cell proliferative responses are detectable in the perip

61 present on the surface of donor DCs, donor T cell proliferative responses are generated only in respo

62 T-cell proliferative responses are inhibited during the er

63 HIV-1-specific CD4+ T cell proliferative responses are not measurable in most

64 mg/kg APAP, these changes plus a potentiated cell-proliferative response are necessary for protection

65 , protective GSH is more abundant, and where cell-proliferative responses are better able to sustain

66 The CD4+ inflammatory T cell proliferative responses as well as CD8+ CTL activit

67 n significantly increased the CEA-specific T-cell proliferative responses as well as the cytolytic T-

68 as negatively associated with HBV-specific T-cell proliferative responses at both time points.

69 y positions induced enhanced specific CD4+ T cell proliferative responses at lower peptide concentrat

70 Despite a compensatory beta-cell proliferative response, beta-cell mass progressivel

71 the regulation of activated CD4(+) T-helper cell proliferative responses; blocking this interaction

72 pe, fail to mount a detectable FV-specific T-cell proliferative response but nevertheless produce FV-

73 eneic MLRs between DCs and T cells reduced T cell proliferative responses but did so less efficiently

74 necrosis factor alpha failed to block the T cell proliferative responses, but anti-IL-2 was strongly

75 timulatory activity for primary and memory T-cell proliferative responses, but this was substantially

76 terized by a lack of virus-specific CD4(+) T-cell-proliferative responses, but strong responses have

77 monocyte (MO) cultures inhibited mitogenic T cell proliferative responses by > 95%.

78 Suppression of CD4(+) T cell proliferative responses by both CD25(+) and CD25(-)

79 e formation prior to the induction of full T cell proliferative responses by concurrent indirect Ag p

80 ory T cells that more efficiently suppress T cell proliferative responses by mixed leukocyte reaction

81 hock-protein peptides elicited significant T-cell proliferative responses by the gamma delta subset o

82 d TM-mediated responses to PECs but induce T-cell proliferative responses characterized largely as TM

83 ells, B cells, or natural killer cells, or T-cell proliferative response compared with interferon bet

84 s showed enhanced suppressive activity for T cell proliferative responses compared with freshly isola

85 H/K ATPase-specific T cell proliferative responses could first be detected 5 w

86 d activation of beta-catenin, and epithelial cell proliferative responses during C. rodentium infecti

87 Suppression of T cell-proliferative responses during malaria has been att

88 kground resulted in a dramatically reduced B cell proliferative response following IgM ligation, char

89 284, 295-314, and 305-324) elicited strong T-cell proliferative responses from all strains of mice wh

90 re, both the magnitude of p24-induced CD4+ T-cell proliferative responses from CD8-depleted PBMC and

91 These p24-induced CD4+ T-cell proliferative responses from CD8-depleted PBMC were

92 emonstrated CMV-specific CD4(+) and CD8(+) T cell proliferative responses from PBMC, with CD4(+)IFN-g

93 induced a rapid increase in NK activity, NK cell proliferative responses, generation of lymphokine-a

94 Our results suggest that the inhibition of T cell proliferative response in microgravity culture is a

95 of GFAP filament assembly and inhibition of cell proliferative response in Muller glia.

96 ptophan (1-mT) results in increased CD4(+) T-cell proliferative response in PBMCs from HIV-infected p

97 developmental abnormality in the epithelial cell proliferative response in those mice.

98 eta fusion cells failed to induce a strong T cell proliferative response in vitro, mainly due to the

99 Interestingly, most HCV-specific CD4 T-cell proliferative responses in AA patients were unaccom

100 HIV-1 Ag-specific CD4(+) T cell proliferative responses in human subjects with adva

101 T-cell proliferative responses in individuals older than 1

102 the CTLp frequency, anti-NP Ab titers, and T cell proliferative responses in mice that were injected

103 f-life becomes apparent during analyses of T cell proliferative responses in mice, particularly when

104 The inhibitory activity of GR1 reduced T cell proliferative responses in MLR and induced Ag-speci

105 on of cell cycle progression and sustained T cell proliferative responses in naive T cell populations

106 epitope, peptide 5 (P5), stimulates strong T cell proliferative responses in subjects with delayed (D

107 rtial BAFF neutralization rescues aberrant B cell proliferative responses in such mice.

108 nd TILN immunization induced specific CD4+ T cell proliferative responses in the iliac lymph nodes, w

109 The peptide also induced LT-B-specific T-cell proliferative responses in these mice.

110 rally marked, but temporary suppression of T-cell proliferative responses in vitro to phytohemaggluti

111 low level of immunogenicity; (4) decreased T-cell proliferative responses in vitro, and (5) did not i

112 Like C1q, HCV core can inhibit T-cell proliferative responses in vitro.

113 sing of DC to efficiently trigger specific T-cell proliferative responses in vitro.

114 ce to generate secondary anti-VSV CTL and Th cell proliferative responses in vitro.

115 nization with this construct elicited CD4+ T cell proliferative responses in vivo.

116 Human HSCs did not stimulate allogeneic T-cell proliferative response, indicating that they are no

117 CD4(+) T-cell proliferative responses indicative of breakdown of

118 ally, both internalization of CD26 and the T cell proliferative response induced by CD26-mediated cos

119 CMX-13 inhibited T cell proliferative responses induced by Con A and alloan

120 The peripheral blood T cell proliferative responses induced by topo I and in vi

121 However, B cell-proliferative responses induced by stimulation of t

122 The results suggest that a strong T-cell proliferative response is induced upon rechallenge

123 blished in male mice: ZP3 peptide-specific T cell proliferative response is reduced and AOD is absent

124 dose levels of vaccine, peptide-specific, T-cell proliferative responses (n = 3) and/or DTH response

125 The enhancement of virus-specific T cell proliferative responses observed in vitro with sing

126 Peripheral blood mononuclear cell proliferative responses of 25 controls and 10 patie

127 T cell proliferative responses of B6.129S1-IL-12rb2(tm1Jm)

128 In contrast with B cells, proliferative responses of CD44(hi) CD8(+) cells

129 ell deficiency did not significantly alter T cell proliferative response or cause a shift in the Th1/

130 nd inguinal lymph nodes, without affecting T cell proliferative responses or levels of anticollagen a

131 ELISpot and T-cell proliferative responses peaked at day 14 and 28 aft

132 The prevention of a myeloma cell proliferative response resulting from inhibition of

133 mmaRIIB only modestly affected initial CD4 T cell proliferative responses, suggesting that FcgammaRII

134 anergy to recall antigens and lower (<70%) T-cell proliferative responses than controls after activat

135 nase-1, which is required for the S3 tubular cell proliferative response that promotes renal repair a

136 resulted in abrogation of hapten-specific T cell proliferative responses that correlated with dimini

137 d of infected individuals, inhibited human T cell proliferative response through interaction with the

138 dendritic cell responses (flow cytometry), T-cell proliferative responses (thymidine incorporation),

139 peptide tolerance suppressed the in vitro T cell proliferative response to AChR and its dominant alp

140 In addition, the T-cell proliferative response to allogeneic LC-derived mDC

141 Functionally, Linc00402 augmented the T cell proliferative response to an allogeneic stimulus bu

142 f T-cell tolerance was assessed by splenic T-cell proliferative response to antigen at 5 weeks.

143 dies against HCV pseudotype virus, a B and T cell proliferative response to antigens, and improved pr

144 otective effect is associated with reduced T-cell proliferative response to B-(9-23) in B-(9-23)-trea

145 wild-type C57BL/6 mice and had an enhanced T cell proliferative response to bovine CII.

146 s little as 5 microM PAHA led to a 10-fold T cell proliferative response to chromatin in short term o

147 that sphingolipids are involved in the beta-cell proliferative response to FA.

148 EGF-like growth factor (HB-EGF) in the beta-cell proliferative response to glucose, a beta-cell mito

149 The T-cell proliferative response to HBcAg did not differ betw

150 ne viral load or CD4+ T cell count and the T cell proliferative response to HIV-1 Gag.

151 iency only partially reduced the naive CD8 T cell proliferative response to IL-15/IL-15Ralpha complex

152 as associated with a significantly reduced T cell proliferative response to mycobacterial Hsp65, whic

153 uction in EAE correlated with a diminished T cell proliferative response to myelin basic protein in t

154 cted with T. gondii developed a gammadelta T cell proliferative response to parasite Ag.

155 RS-1 nor IRS-2 overexpression induced a beta-cell proliferative response to TGF-alpha/EGF.

156 cretion and were unable to induce a normal T cell proliferative response to TT.

157 but two patients made primary antibody and T-cell proliferative responses to a foreign antigen admini

158 lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion i

159 immunocompromised, with reduced polyclonal T cell proliferative responses to alloantigen, defined pep

160 17 receptor (R):Fc fusion protein inhibits T-cell proliferative responses to alloantigens and prolong

161 m four different colonies side-by-side for T-cell proliferative responses to an expanded panel of aut

162 ell functions including IL-2 secretion and T cell proliferative responses to CD28 plus T cell recepto

163 Assays were performed to study T cell proliferative responses to CII in peripheral blood

164 T cell proliferative responses to diabetes-associated Ags

165 We compare changes in lymphocyte subsets, T cell proliferative responses to disease-associated targe

166 iltration into grafts but not with altered T-cell proliferative responses to donor stimulators.

167 The induction of CD4+ T cell proliferative responses to eight synthetic peptides

168 iding sufficient help to allow optimal CD8 T cell proliferative responses to exosomal protein.

169 /- --> F1 chimeras were also able to mount T-cell proliferative responses to foreign antigens equal t

170 rst, neither APC type was able to initiate T cell proliferative responses to full-length native Topo

171 The human T cell proliferative responses to GA were HLA class II DR-

172 nd untreated MS patients exhibit prominent T cell proliferative responses to GA.

173 kinase proto-oncogene, reportedly modulates cell proliferative responses to growth factors, contract

174 T-cell proliferative responses to HER-2/neu peptides and i

175 It has been suggested that CD4+ T cell proliferative responses to HIV p24 Ag may be import

176 elper lymphocytes, manifested by increased T cell proliferative responses to HIV-1 Gag and recall ant

177 A range of T-cell proliferative responses to HPV-11 VLP were observed

178 ever, it has been difficult to demonstrate T cell proliferative responses to human insulin in IDDM pa

179 Their peripheral blood mononuclear cell proliferative responses to immunogen stimulation 4

180 in, saliva IgA binding to insulin, or CD4+ T-cell proliferative responses to insulin were observed in

181 nd saliva IgA binding to insulin, and CD4+ T-cell proliferative responses to insulin.

182 of 25 tested persons made antigen-specific T cell proliferative responses to L2E7, and peripheral blo

183 B-cell proliferative responses to lipopolysaccharide were

184 fter the transplantation of thymus tissue, T-cell proliferative responses to mitogens developed in fo

185 All 7 survivors developed T-cell proliferative responses to mitogens of more than 10

186 L-12 significantly increased PBMC and CD4+ T cell proliferative responses to p24 Ag in HIV-infected,

187 T cell proliferative responses to purified HHV-8 were meas

188 T-cell proliferative responses to SIV gp140 and T-helper e

189 granule precursor cells and enhances granule cell proliferative responses to Sonic hedgehog.

190 oavailability facilitated the induction of T cell proliferative responses to suboptimal stimuli.

191 ventilatory acclimatization and carotid body cell proliferative responses to sustained hypoxia.

192 T-cell proliferative responses to synthetic peptides demon

193 acrophages and DCs directly regulate human B-cell proliferative responses to T-cell-independent stimu

194 Primary T cell proliferative responses to TCR ligation plus CD28 c

195 Eleven of the 21 patients also developed T cell proliferative responses to the homologous self-Ag.

196 CD4 T cell proliferative responses to the pneumococcal protein

197 Considerable heterogeneity in the T-cell proliferative responses to these three variant anti

198 s, inhibition of SIV replication, and CD4+ T cell proliferative responses to three of the extracellul

199 T cell proliferative responses to topo I were detected in

200 w also had a reduced capacity to stimulate T cell proliferative responses to tubercle bacillus Ag 85.

201 lidated linear discriminant analysis using T cell proliferative responses to two regions of Tri r 2 (

202 munization, respectively), in increases in T cell-proliferative response to HPV-16 L1 VLPs (P<.001).

203 rosis, but had no inhibitory effect on the T cell-proliferative response to myelin basic protein (MBP

204 T cell-proliferative responses to a single epitope, HEL47-

205 nt than untreated DCs in driving syngeneic T cell-proliferative responses to staphylococcal enterotox

206 detected by inhibition of the Ag-specific T cell proliferative response upon Ag presentation by IFN-

207 lity to enhance anti-CD3-stimulated CD4(+) T cell proliferative responses via B7-1 and B7-2.

208 ificant revival of antigen specific CD4(+) T cell proliferative response was observed after reconstit

209 ability to transduce CLL cells, a vigorous T-cell proliferative response was obtained using cells tra

210 endritic cells (DCs) to induce Ag-specific T cell proliferative responses was significantly reduced c

211 ed subsets of lymphocytes and quantitative T-cell proliferative response were assessed in an explorat

212 ti-IgM- and anti-CD40 plus anti-Ig-induced B cell proliferative responses were decreased in BXD2-Aicd

213 r neutralizing antibodies nor SIV-specific T-cell proliferative responses were detectable in any of t

214 ll as anti-HLA-A2 antibody development and T cell proliferative responses were determined at days +5,

215 delayed-type hypersensitivity and splenic T cell proliferative responses were examined, Peyer's patc

216 V core epitopes; however, the humoral and Th cell proliferative responses were found to be weak.

217 Overall, cell proliferative responses were influenced by both the

218 oy islet tissue in vivo though spontaneous T-cell proliferative responses were observed in prediabeti

219 rsistent, and vigorous HIV-1-specific CD4+ T cell proliferative responses were present, resulting in

220 T cell proliferative responses were seen with all encephal

221 Furthermore, specific CD4(+) and CD8(+) T cell proliferative responses were significantly increase

222 In these animals, MOG-specific T cell proliferative responses were transiently suppressed

223 a significant increase in PBLs, but T and B cell-proliferative responses were not consistently enhan

224 ture DCs were used to stimulate allogeneic T cells, proliferative responses were dampened (approximat

225 sole class II molecule generated a robust T cell-proliferative response when primed with peptide 2 o

226 newborn blood specimens tested also showed T cell proliferative responses, which included a marked ex

227 h specific impairment of ex vivo antidonor T cell proliferative responses, which was not reversed by

228 These data suggest that Ply induces CD4 T cell proliferative responses with production of IFN- gam

229 e absence of strong HIV-1-specific, CD4(+) T-cell-proliferative responses, yet the mechanism underlyi